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Abstract
Recent success with B cell depletion therapies has revitalized efforts to understand the
pathogenic role of B cells in Multiple Sclerosis (MS). Using the adoptive transfer system of
experimental autoimmune encephalomyelitis (EAE), a murine model of MS, we have previ-
ously shown that mice in which B cells are the only MHCII-expressing antigen presenting
cell (APC) are susceptible to EAE. However, a reproducible delay in the day of onset of dis-
ease driven by exclusive B cell antigen presentation suggests that B cells require optimal
conditions to function as APCs in EAE. In this study, we utilize an in vivo genetic system to
conditionally and temporally regulate expression of MHCII to test the hypothesis that B cell
APCs mediate attenuated and delayed neuroinflammatory T cell responses during EAE.
Remarkably, induction of MHCII on B cells following the transfer of encephalitogenic CD4 T
cells induced a rapid and robust form of EAE, while no change in the time to disease onset
occurred for recipient mice in which MHCII is induced on a normal complement of APC sub-
sets. Changes in CD4 T cell activation over time did not account for more rapid onset of
EAE symptoms in this new B cell-mediated EAE model. Our system represents a novel
model to study how the timing of pathogenic cognate interactions between lymphocytes
facilitates the development of autoimmune attacks within the CNS.
Introduction
Multiple sclerosis (MS) is a debilitating autoimmune disease of the central nervous system
(CNS) with an unknown etiology despite being the subject of intense study for over a century
[1]. MS is characterized by the chronologically and spatially distinct formation of lesions (“pla-
ques”) comprised of cellular and humoral inflammation, demyelination, and axonal damage.
Experimental autoimmune encephalomyelitis (EAE) is the main animal model for MS used to
investigate the cellular mechanisms of disease as well as to develop new MS treatments [2, 3].
Early experiments with EAE identified the CD4 T cell as both necessary and sufficient for
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disease and prompted further investigation into the characteristics of MHCII+ antigen pre-
senting cells (APCs) responsible for the regulation of CD4 T cell behavior during neuro-
inflammation [4].
In MS, B cell depletion therapies (BCDTs) have recently been shown to be highly effective
at amelioration of disease [5, 6]. BCDT reduces relapses and decreases inflammatory lesions
[5, 7] but does not affect cerebral spinal fluid (CSF) levels of immunoglobulin nor deplete the
long-lived antibody-secreting plasma cells from within the CSF or other tissues [8, 9]. Various
approaches with BCDT in EAE also demonstrate that B cells can have an enormous influence
on cognate encephalitogenic T cell pathogenicity and highlight the importance of antibody-
independent B cell functions for the pathogenesis of CNS autoimmunity [10–12]. B cells are
not highly phagocytic yet are very efficient at presenting antigens acquired via receptor-medi-
ated endocytosis [13–15]. Although the target antigens for MS are unknown, recombinant B
cell receptors (BCRs) derived from CSF-localized B cell clones exhibit specificity for myriad
CNS components [16–19]. Through the process of linked recognition, a non-auto-reactive B
cell could still present self-peptide antigens associated with internalized immune complexes to
activate auto-reactive CD4 T cells [20]. Understanding how B cell-mediated antigen presenta-
tion influences neuro-inflammation and tolerance in MS could lead to potent and more spe-
cific immunomodulatory therapies.
Our previous work demonstrated that B cells are capable of serving as the only APC during
passive EAE [15]. However, transgenic mice with elevated B cell specificity for MOG (IgHMOG
mice) crossed to mice expressing MHCII exclusively by CD19+ B cells (CD19-BMHCII mice)–
referred to as CD19-BMHCIIxIgHMOG mice because CD19Cre drives MHCII expression on B
cells–develop passive EAE with a statistically significant and reproducible delay in onset com-
pared to WT mice [15]. Thus, B cells are capable of propagating auto-antigen-specific CNS
demyelination on their own but may be limited in their efficiency as APCs. To explore the
kinetics of B cell cognate interactions during EAE, BMHCIIxIgHMOG mouse were bred to a
Tamoxifen (Tam)-inducible CD20Tam-Cre murine reagent generated by Shlomchik and col-
leagues [21]. By carefully controlling of the timing of cognate interactions between B cells and
CD4 T cells during EAE, we have observed a rapid induction of disease, demonstrating that B
cells can efficiently drive auto-reactive CD4 T cell responses targeting the CNS.
Materials & methods
Mice
WT C57BL/6 (B6) mice, MOG-specific TCR-transgenic (2D2) mice, and UBCTam-Cre mice
were obtained from The Jackson Laboratory (Bar Harbor, ME). CD19-BMHCIIxIgHMOG mice,
in which B cells expressing a transgene driving a MOG-specific BCR exclusively express
MHCII, were generated as previously reported [15]. CD20Tam-Cre mice [21] were bred to IAßb-
stopflox/floxxIgHMOG mice [15] to generate CD20-BMHCIIxIgHMOG and UBCTam-Cre mice were
bred to IAßbstopflox/flox mice to obtain UBCMHCII mice [21, 22]. Littermates from IAßbstopflox/flox-
xIgH
MOG
crossed to CD20Tam-CrexIAßbstopflox/flox breedings were used for comparison during
experiments. 2D2 mice were crossed with CD19-BMHCIIxIgHMOG mice, which lack a complete
endogenous CD4 T cell compartment. Three-week-old 2D2xCD19-BMHCIIxIgHMOG progeny
received a thymic transplant from WT animals to support 2D2 thymocyte development as previ-
ously described, and were harvested after 8–12 weeks [23]. Animals were housed in a specific
pathogen-free barrier facility at the Washington University School of Medicine (WUSM). All
breeding and experimental protocols were performed in accordance with protocols reviewed and
approved by the WUSM Animal Studies Committee/Institutional Animal Care and Use Commit-
tee (IACUC). Death was not considered an experimental outcome for any of the experiments
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reported herein. Nevertheless, humane endpoints were considered for all experiments, and accord-
ing to IACUC protocols all experiments were designed to minimize suffering and distress of mice.
EAE
Active EAE with rhMOG (Children’s Hospital of Pennsylvania) was induced by s.c. immuniza-
tion of 150 μg rhMOG protein (residues 1–125 of human MOG protein [23]) emulsified in
CFA (Sigma, St. Louis, MO). Mice received 200ng Pertussis toxin (Enzo, Farmingdale, NY) i.p.
at the time of immunization and 48h later. Passive EAE was induced by adoptive transfer of
5x106 MOG-specific Thy1.1+ or CD45.1+ encephalitogenic CD4 T cells, as previously reported
[23]. Transfer experiments in which encephalitogenic donor T cells were ‘rested’ in vivo in an
MHCII-deficient host were performed by initially transferring 5x106 encephalitogenic CD4 T
cells into MHCII-deficient IAßbstopflox/floxxIgHMOG mice. Three weeks later, CD4 T cells were
isolated from those mice and immediately to transferred into CD19-BMHCIIxIgHMOG or WT
mice. In other experiments, MHCII expression was induced in UBCMHCII and CD20-BMHCIIx-
IgHMOG mice by oral gavage with 5mg Tam in 50μL corn oil. Tam was either administered
three days prior to donor T cell transfer or at various time points after donor T cell transfer.
MHCII expression was verified by flow cytometric analysis of blood collected from the cheek.
Mice were observed daily and clinical scores were determined by a five point scoring system, as
follows: 0 = no disease; 1 = limp tail; 2 = mild hind limb paresis; 3 = severe hind limb paresis;
4 = complete hind limb plegia or quadriplegia; 5 = moribund or dead.
Flow cytometry
Spleens were harvested from Avertin-anesthetized mice and single cell suspensions were
treated with ACK erythrocyte lysis buffer. Mice were perfused with 25mL of ice-cold PBS and
CNS tissues were isolated. Mononuclear cells were purified from homogenized brains and spi-
nal cords by centrifugation for 30 min in 30% Percoll (GE Healthcare) solution as previously
reported [22]. Cells were incubated with the anti-Fc receptor antibody 2.4G2 prior to the addi-
tion of staining antibodies. Intracellular cytokine (BD Cytofix/Cytoperm Plus, BD Biosciences,
San Diego CA) and FoxP3 staining (Mouse Regulatory T cell Staining Kit #1, eBioscience San
Diego, CA) of donor CD4 T cells was performed in accordance with kit protocols. The follow-
ing anti-mouse antibodies were purchased from BD Biosciences (San Jose, CA): anti-CD69
FITC clone H1.2F3, anti-CD45 FITC, anti-GR-1 PE clone RB6-8C5, anti-CD3e PE-CF594
clone 145.2C11, anti-B220 PE-CF594 clone RA3-6B2, anti-CD44 PerCP/Cy5.5 clone IM7,
anti-CD19 APC clone 1D3. The following antibodies were purchased from eBioscience (San
Diego, CA): anti-CD45.1 FITC clone A20, anti-Foxp3 PE clone FJK-16s, rat anti-IgG2a isotype
PE clone eBR2a, anti-CD25 APC clone PC61.5, anti-IFNγ APC clone XMG1.2. The following
antibodies were purchased from BioLegend (San Diego, CA): anti-IL-17 FITC clone TC11-
18H10.1, anti-CD4 clone GK1.5 in FITC and BV 421, anti-CD19 PE clone 1D3, anti-GM-CSF
PE clone MP1-22E9, anti-CD49d clone R1-2 in PE and PE/Cy7, anti-Thy1.1 PerCP clone OX-
7, anti-CD11b clone M1.7 in PerCP/Cy5.5 and PE/Cy7, anti-GR-1 PE/Cy7 clone RB6-8C5,
anti-MHCII clone M5/114.15.2 in AF700 and Pacific Blue, anti-CD44 AF700 clone IM7, anti-
CD8α APC/Cy7 clone 53.6.7, anti-CD45 AF700 clone 30-F11 in AF700, Pacific Blue, and BV
510. Cells were acquired on a Gallios flow cytometer (Beckman Coulter) and analyzed with
FlowJo software version 8.5.2 (TreeStar, Ashland, OR) with doublets excluded.
Histology and immunofluorescence
Mice were sacrificed and perfused with 25mL ice cold PBS followed by 20mL 4% paraformal-
dehyde (Sigma-Aldrich). Spinal cord tissue was removed from the vertebrae and then fixed in
Rapid B cell-mediated EAE
PLOS ONE | https://doi.org/10.1371/journal.pone.0199694 June 26, 2018 3 / 20
4% paraformaldehyde for more than 12 hours, followed by dehydration in 30% sucrose for 48
hours. The tissue was embedded in optimal cutting temperature media (TissueTek, Torrence,
CA) and cut at 8–10μm thick sections using a Leica CM1900 cryostat (Germany). The WUSM
Developmental Biology Histology & Microscopy Core stained sections with Luxol Fast Blue to
detect myelin. Slides were examined by light microscopy using a Nikon 90i motorized upright
digital microscope with camera and Metamorph software (Molecular Devices). Sections were
also stained to quantify myelinated white matter using goat anti-MOG (Invitrogen) with iso-
type control goat IgG2a (abcam) and secondary antibody donkey anti-goat Alexa-555 (Invitro-
gen). Slides were mounted with Fluoroshield Mounting Medium with DAPI (abcam). Slides
were examined by immunofluorescent microscopy using a Nikon 90i motorized upright digi-
tal microscope with CoolSNAP ES2 camera (Photometrics). Inflammation score was recorded
by blinded observer using the following scale system: 0 = normal, no inflammation; 1 = mild
inflammation with a few small regions of increased cellularity; 2 = moderate inflammation
with one large lesion or several smaller inflammatory foci; 3 = severe inflammation with dense
parenchymal infiltration and many large lesions; 4 = massive inflammation in which most of
the white matter has dense cellularity. Demyelination was quantified by blinded calculation of
lesion area in thoracic spinal cord sections using Metamorph software (Molecular Devices,
Inc).
Statistical analysis
All data generated are reported as mean ± the standard error of the mean (SEM). Unpaired t-
tests were used for comparison of cellular infiltrates. Time-to-EAE-onset incidence curves
were compared by Log-rank (Mantel-Cox) tests. Group effects were compared via analysis of
variance (ANOVA) with Tukey’s test or Kruskal-Wallis test with Dunn’s test for multiple com-
parisons when assumptions were not violated. Mann-Whitney tests with two-tailed P values
were performed for flow cytometry assays quantifying lymphocytes in the CNS. All statistical
analyses were completed using PRISM 7 software (GraphPad).
Results
B cell antigen presentation is insufficient to initiate spontaneous
autoimmune CNS demyelination
Increasing the frequency of MOG-specific B cells in 2D2 mice, in which T cell receptors are
highly specific for MOG, routinely leads to spontaneous inflammatory demyelination within
the spinal cord and optic nerve, indicating that naïve MOG-specific B and T cells collaborate
to induce neuro-inflammation [24, 25]. Additionally, transgenic SJL/J mice with MOG-spe-
cific T cells require an intact B cell compartment for susceptibility to spontaneous EAE [26].
To test the hypothesis that antigen presentation by B cells can independently trigger spontane-
ous EAE, we crossed CD19-BMHCIIxIgHMOG with 2D2 mice and salvaged 2D2 CD4 T cell
development in progeny by thymus transplant. While both 2D2 and 2D2xIgHMOG mice with
WT MHCII expression spontaneously developed optic neuritis, only 2D2xIgHMOG mice
developed spontaneous EAE, confirming previously published data (Table 1). However,
2D2xCD19-BMHCIIxIgHMOG mice were completely resistant to both optic nerve inflammation
and spontaneous EAE (Table 1) despite a substantial reconstitution of the CD4 T cell compart-
ment with MOG-specific T cells as reported [23]. These results suggested that antigen-specific B
cells alone were not sufficient to elicit CD4 T cell-dependent spontaneous inflammatory demye-
lination within the CNS, even when a high frequency of cognate, auto-reactive T cells were pres-
ent. When these data are considered in conjunction with our previous observation that EAE is
Rapid B cell-mediated EAE
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delayed in CD19-BMHCIIxIgHMOG mice [15], it suggests that B cells are intrinsically less efficient
than other APCs in their ability to initiate and direct CD4 T cell auto-reactivity to MOG.
Tamoxifen-inducible systems for induction of MHCII expression
By breeding the IAßbstopflox/floxxIgHMOG mouse to Tam-inducible CD20Tam-Cre mice, we
aimed to temporally regulate MHCII expression exclusively by B cells. To assess the efficiency
of recombination at the IA-ß locus following Tam administration, peripheral blood was col-
lected from CD20-BMHCIIxIgHMOG and UBCMHCII mice prior to oral gavage with Tam and at
various time points thereafter. MHCII expression was undetectable prior to Tam treatment for
both CD20-BMHCIIxIgHMOG and UBCMHCII mice similar to the two hour timepoint (Fig 1A).
52.3 ± 4.7% (Mean ± SEM) of B cells from CD20-BMHCIIxIgHMOG mice expressed MHCII 24
hours after Tam administration (Fig 1A). After 72 hours, the mean frequency of MHCII+ B
cells in CD20-BMHCIIxIgHMOG spleens (89.3 ± 1.4%) was similar to that of WT (84.5 ± 1.8%)
and CD19-BMHCIIxIgHMOG mice (94.3 ± 1.5%) (Fig 1B). Following Tam administration, fewer
B cells in UBCMHCII mice expressed MHCII compared to WT B cells, yet MHCII was induced
on other APC subsets in UBCMHCII mice (Fig 1B).
B cell-mediated EAE is delayed in CD20-BMHCIIxIgHMOG mice
Based on the high efficiency of MHCII induction by Tam administration, we hypothesized
that expression of MHCII by B cells in CD20-BMHCIIxIgHMOG mice would manifest EAE simi-
lar to CD19-BMHCIIxIgHMOG mice. Thus, we treated CD20-BMHCIIxIgHMOG mice and
UBCMHCII mice with Tam three days prior to the adoptive transfer of encephalitogenic T cells.
In WT mice, adoptive transfer of encephalitogenic CD4 T cells typically resulted in clinical
and pathological signs within 10 days (Fig 2A). The time to onset and disease course for WT
and UBCMHCII mice treated with Tam prior to the adoptive transfer of CD4 T cells were not
significantly different (Fig 2B and 2C). As previously reported, CD19-BMHCIIxIgHMOG mice
exhibited a statistically significant delay in the day of onset of EAE compared to WT mice, with
EAE signs beginning on average at 15.0 ± 1.0 days following transfer of donor T cells [15].
CD20-BMHCIIxIgHMOG mice treated with Tam before T cell transfer exhibited similar disease
kinetics, with an average day of EAE onset of 15.8 ± 0.9 days (Fig 2B and 2C). Hence, in our
Tam-inducible MHCII system, B cell-restricted MHCII expression requires an extended period
of time to facilitate disease mediated by encephalitogenic CD4 T cells compared to a full comple-
ment of MHCII+ APC subsets. These results indicate that the conditional and temporal regula-
tion of MHCII in vivo is suitable for investigating the timing of B cell involvement during EAE.
B cells are capable of inducing accelerated onset EAE
Antigen acquisition and presentation by B cells is implicated as a critical precursor to CD4 T
cell activation and demyelination in B cell-dependent models of EAE [27–29]. It is possible
Table 1. B cells are not sufficient APCs to support spontaneous EAE or optic neuritis.
Genotype Optic Neuritis Thymus Transplant Spontaneous EAE
2D2 5/11 No 0/11
2D2xIgHMOG 3/3 No 15/19
2D2xCD19-BMHCIIxIgHMOG 0/19 Yes 0/21
WT hMOG 3/5 No 5/5
 Active EAE (not spontaneous)
https://doi.org/10.1371/journal.pone.0199694.t001
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that B cells require more time to collect and process antigen because they are generally seques-
tered in peripheral lymphoid tissues where CNS antigens are less accessible. We reasoned that
B cell-mediated EAE would be delayed regardless of when MHCII expression was induced rel-
ative to CD4 T cell transfer. To test this, encephalitogenic CD4 T cells were transferred into
Fig 1. Temporal regulation of MHCII expression in vivo. (A) MHCII expression on peripheral blood B cells collected from UBCMHCII (red line) and
CD20-BMHCIIxIgHMOG (blue shaded) at several time points after Tam administration. Data are representative of two experiments, (n = 2 mice per time point from each
genotype). (B) 72 hours post Tam treatment, spleens were harvested from naïve mice 72 hours after oral gavage with Tam for UBCMHCII (red squares) and
CD20-BMHCIIxIgHMOG (blue circles) or corn oil vehicle for WT (black squares) and CD19-BMHCIIxIgHMOG mice (grey circles). The frequency of MHCII+ B cells as a
percentage of total B cells is presented as mean ± SEM from n = 3 mice per genotype.
https://doi.org/10.1371/journal.pone.0199694.g001
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CD20-BMHCIIxIgHMOG mice and UBCMHCII mice prior to the induction of MHCII expression.
No animals developed EAE prior to Tam treatment. Regardless of the amount of time between
CD4 T cell transfer and Tam-induced MHCII expression, the time to EAE onset for UBCMHCII
mice after Tam administration was not significantly different; the average day of EAE onset
Fig 2. Tam-inducible MHCII expression models recapitulate WT and B-cell mediated adoptive transfer EAE models. (A) Mean ± SEM EAE scores recorded for
CD20-BMHCIIxIgHMOG (blue circles), and UBCMHCII (red squares) mice treated with Tam by oral gavage and WT (black squares), CD19-BMHCIIxIgHMOG (grey circles),
treated with corn oil vehicle by oral gavage once, three days prior to receiving 5x106 encephalitogenic CD4 T cells. Data is representative of three independent
experiments with n = 3–5 mice per genotype. (B) Day of EAE onset post cell transfer for WT (black squares), UBCMHCII (red squares), CD19-BMHCIIxIgHMOG (grey
circles) treated with corn oil 72 hours prior to CD4 T cell transfer and CD20-BMHCIIxIgHMOG (blue circles) recipient mice treated with Tam 72 hours prior to CD4 T
cell transfer. Graph shows mean day of onset ± SEM from two pooled, independent experiments with n = 2–4 mice per genotype. Unpaired t test performed to compare
day of onset between WT and CD19-BMHCIIxIgHMOG mice. (C) Mice were treated with Tam 72 hours prior to CD4 T cell transfer. Time to EAE onset for WT (black)
and UBCMHCII (red) mice is not significantly different by log-rank test (p = 0.107). Time to EAE onset for CD19-BMHCIIxIgHMOG (grey), and CD20-BMHCIIxIgHMOG
(blue) mice is not significantly different by log-rank test (p = 0.481). Incidence curves generated from two pooled, independent experiments with n = 2–4 mice per
genotype.
https://doi.org/10.1371/journal.pone.0199694.g002
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for UBCMHCII mice treated with Tam one week after T cell transfer was 6.0 ± 0.4 days post
Tam, whereas the average for mice treated with Tam after two or three weeks post T cell trans-
fer was 5.6 ± 0.3 days and 5.7 ± 0.3 days post Tam, respectively (Fig 3A and 3B). Surprisingly,
we observed a rapid onset of EAE signs for CD20-BMHCIIxIgHMOG mice that was dependent
on the length of time between T cell transfer and MHCII induction (Fig 3A and 3B). The
mean day of onset for CD20-BMHCIIxIgHMOG mice was significantly delayed compared to
UBCMHCII mice when Tam was administered at either week one or week two after T cell trans-
fer (Fig 3A). However, when mice received Tam three weeks after CD4 T cell transfer, the
mean time to EAE onset for CD20-BMHCIIxIgHMOG and UBCMHCII mice was not significantly
different (Fig 3B). These results demonstrate that B cell-mediated EAE has the capacity to
develop more quickly than even the conventional WT passive EAE model. Thus, our Tam-
inducible MHCII expression system provides a means to assess the kinetic differences in
neuro-inflammation coordinated by antigen-specific B cells.
Fig 3. Tam treatment after T cell transfer results in accelerated B cell mediated EAE. (A) Mean ± SEM day of EAE onset for WT (black squares) and
CD19-BMHCIIxIgHMOG (grey circles) post T cell transfer, and for UBCMHCII (red squares) and CD20-BMHCIIxIgHMOG (blue circles) treated with Tam at either one week,
two weeks, or three weeks post T cell transfer. Data is pooled from 12 different experiments with n = 1–5 mice per genotype and time point evaluated, p values calculated
by unpaired t tests. (B) Time to EAE onset is not significantly different for UBCMHCII mice (left graph) treated with Tam at either Week 1 (solid line), Week 2 (dashed
line), or Week 3 (dotted line) post CD4 T cell transfer. Time to EAE onset is significantly delayed for CD20-BMHCIIxIgHMOG mice (right graph) treated with Tam at
either Week 1 (solid line), compared to Week 2 (dashed line), or Week 3 (dotted line) post CD4 T cell transfer. Incidence curves generated from is pooled from 12
different experiments with n = 1–5 mice per genotype and time point, with significance evaluated by log-rank test.
https://doi.org/10.1371/journal.pone.0199694.g003
Rapid B cell-mediated EAE
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Accelerated EAE is not due to immune cell trafficking to the CNS prior to
Tam administration
A low frequency of CNS MHCII+ B cells can support neuro-inflammation in CD19-BMHCIIx-
IgHMOG mice with EAE [15]. Localization to the CNS compartment prior to Tam administra-
tion would give a small number of B cells ready access to both MOG antigens and cognate T
cells primed to respond rapidly upon MHCII expression by the B cells. Hence, antigen-specific
lymphocytes entering the CNS over time prior to the induction of MHCII expression could
explain the increasingly rapid onset of EAE signs observed in CD20-BMHCIIxIgHMOG mice. To
assess this possibility, the spinal cords of CD20-BMHCIIxIgHMOG mice and UBCMHCII mice
were examined for inflammation and demyelination before and after treatment with Tam
three weeks post-T cell transfer. Histological examination of these tissues did not reveal any
signs of inflammation or demyelination prior to Tam treatment (Fig 4A). Both
CD20-BMHCIIxIgHMOG mice and UBCMHCII mice that developed EAE after receiving Tam on
week three post-T cell transfer had similar inflammatory foci (Fig 4A and 4B). Semi-quantita-
tive assessment of inflammation of the spinal cord at the level of the brainstem and cervical,
thoracic, and lumbar regions of the spinal cord revealed similar degrees of inflammation (Fig
4C). However, we observed a significant difference in the extent of inflammation between the
genotypes at the thoracic level (Fig 4B). The difference in area of demyelinated white matter
within the thoracic spinal cords of CD20-BMHCIIxIgHMOG and UBCMHCII mice with EAE was
significantly different, though this could be due to a higher mean EAE score for the UBCMHCII
mice (3.33 ± 0.4 vs. 2.4 ± 0.3) (Fig 4D). These observations were verified by flow cytometric
analyses of the composition of infiltrating mononuclear cells in brain and spinal cord tissues
examined prior to Tam treatment at various time points post T cell transfer (Fig 5 and S1 Fig).
UBCMHCII, CD20-BMHCIIxIgHMOG, and MHCII deficient Cre-IAßbstopflox/floxxIgHMOG litter-
mate control mice were harvested one, two, or three weeks post T cell transfer but prior to
Tam treatment and brains and spinal cords were analyzed by flow cytometry to detect infiltrat-
ing B cells and donor CD4 T cells. Prior to Tam treatment, these recipient mice are all MHCII-
deficient and analysis of donor T cell cytokine production after incubation in different geno-
types does not indicate that the genotype of the recipient influences encephalitogenicity over
time (Fig 6 and S2 Fig). While the mean frequency of B cells in the brain at week two post cell
transfer was significantly different compared to week one post cell transfer (p< 0.01), there
was no difference at week three and no overall increase in the frequency of lymphocytes in the
CNS over time prior to Tam treatment (Fig 5A). Altogether, very few infiltrating lymphocytes
were detected in the brain and spinal cord before MHCII expression was induced, and the cel-
lular composition of CNS tissues from experimental mice was comparable to the number of B
cells and endogenous CD4 T cells detected in the CNS of naïve WT mice (S1 Fig). Taken
together this suggests that the rapid onset of disease is not a result of anticipatory migration of
CD4 T or B cells into the CNS. Flow cytometry of CNS tissues harvested from CD20-BMHCIIx-
IgHMOG mice three days post-EAE onset showed that the frequency of B cells in the brains and
spinal cords tended to be more variable when Tam is administered soon after T cell transfer
(Fig 5B–5D). Additionally, although there is a higher frequency of B cells in the CNS of
CD20-BMHCIIxIgHMOG mice with EAE when treated with Tam two weeks after T cell transfer
(Fig 5C), the difference is not apparent when treated with Tam three weeks after T cell transfer
(Fig 5D). These results suggest that the rapid onset of EAE signs observed in CD20-BMHCIIx-
IgHMOG mice treated with Tam weeks after T cell transfer is not the result of enhanced locali-
zation of B cells or T cells in the CNS compartment.
Rapid B cell-mediated EAE
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Changes in donor T cells over time do not account for rapid onset of B cell-
mediated EAE
It is possible that donor encephalitogenic CD4 T cells become more pathogenic over time
prior to MHCII induction in CD20-BMHCIIxIgHMOG mice. To rule out the possible effects of
increasing donor CD4 T cell activation, peripheral CD4 T cell markers were assayed by flow
cytometry at various time points post-transfer and prior to Tam administration. The mean
fluorescence intensity (MFI) of CD44, a marker of effector-memory CD4 T cells, increased
over time while CD69, a marker of T cell activation, decreased over time (Fig 6A and 6D). The
MFI of two other markers, CD62L, which is expressed by naïve T cells homing to secondary
lymphoid tissues, and CD25, expressed by activated T cells and regulatory T cells, also
decreased over time in MHCII deficient recipients prior to Tam administration (Fig 6B and
6C). Hence, deviations in activation status were observed in donor CD4 T cells after incuba-
tion in MHCII-deficient hosts. However, a mixture of changes, inconsistent with a selection of
a singular population of activated encephalitogenic CD4 T cells, was observed after prolonged
incubation in the absence of cognate interactions.
Subsequently, we reasoned that if the pre-Tam time period induces changes in donor T
cells to enhance their encephalitogenic potential, we would then be able to induce rapid-onset
EAE in WT or CD19-BMHCIIxIgHMOG mice by re-transferring the T cells into new naïve hosts.
If the observed changes in donor T cells are responsible for the increasingly rapid EAE onset
observed in CD20-BMHCIIxIgHMOG mice, donor T cells collected after an initial incubation in
an MHCII-deficient host would induce rapid-onset EAE after a subsequent passive transfer
into naïve recipients. Therefore, MHCII deficient Cre-IAßbstopflox/floxxIgHMOG mice received
encephalitogenic CD4 T cells, which were harvested from spleens and lymph nodes after three
weeks of in vivo incubation. These freshly isolated T cells were MACS-purified by CD4 positive
selection and immediately transferred into naïve WT or CD19-BMHCIIxIgHMOG recipients.
The average day of onset was 18.2 for CD19-BMHCIIxIgHMOG receiving encephalitogenic CD4
T cells rested for three weeks in a MHCII-deficient environment, similar to the day of onset
described previously for CD19-BMHCIIxIgHMOG mice receiving freshly in vitro generated
donor CD4 T cell lines (Table 2). Likewise, the day of onset for WT and UBCMHCII mice was
similar to the day of onset for WT mice whether donor CD4 T cells were rested in vivo for
three weeks or transferred immediately. Flow cytometry to detect intracellular cytokines
revealed the frequency of IFNγ-producing donor T cells harvested three weeks after transfer
into an MHCII-deficient recipient is drastically reduced compared to the frequency of cyto-
kine-producing donor CD4 T cells prior to transfer. This same reduction in IFNγ production
was observed in CD4 T cells harvested from CD20-BMHCIIxIgHMOG and UBCMHCII mice prior
to Tam administration (Fig 6E and S2 Fig). Taken together, the data indicate that prolonged
Fig 4. Inflammation and demyelination is not evident in spinal cords of encephalitic CD4 T cell recipients prior to Tam administration. (A)
Representative spinal cord sections from recipients of encephalitogenic CD4 T cells (n = 5, CD20-BMHCIIxIgHMOG mice; n = 6, UBCMHCII mice) were
stained with Luxol Fast Blue, scale bar = 100um; all images generated from 10x magnification. (A) Spinal cords from CD20-BMHCIIxIgHMOG mice
harvested three weeks after T cell transfer and before Tam administration (left). CD20-BMHCIIxIgHMOG mice treated with Tam three weeks after T cell
transfer (middle) and harvested three days post EAE onset. UBCMHCII mice treated with Tam three weeks after T cell transfer (right) and harvested three
days post EAE onset. (B) Representative spinal cord sections from recipients of encephalitogenic CD4 T cells (at least mice 5 per genotype) were stained
with antibodies to detect MOG, scale bar = 100um. Spinal cords from CD20-BMHCIIxIgHMOG mice (top left) and UBCMHCII mice (bottom left) harvested
three weeks after T cell transfer and before Tam administration. CD20-BMHCIIxIgHMOG (top right) and UBCMHCII (bottom right) mice treated with Tam
three weeks after T cell transfer and harvested three days post EAE onset. (C) Regions from rostral to caudal sections of spinal cords from
CD20-BMHCIIxIgHMOG (blue) and UBCMHCII mice (red) were harvested and scored for inflammation. Graph shows mean +/- SEM inflammation scores
and Kruskal-Wallis test with Dunn’s correction for multiple comparisons was applied. B.S. = brainstem; C = cervical; T = thoracic; L = lumbar. (D) Mean
(SD) percent area of demyelinated white matter was quantified for thoracic spinal cord sections from CD20-BMHCIIxIgHMOG (blue) and UBCMHCII (red)
mice. Significance determined by Mann-Whitney test with two-tailed p value.
https://doi.org/10.1371/journal.pone.0199694.g004
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Fig 5. Flow cytometric analysis of lymphocytes from brains (left) and spinal cords (right). (A) Mean ± SEM frequency of B cells and donor CD4 T cells as a percent
of total mononuclear cells in the CNS of mice at week 1 (circles), week 2 (squares), or week 3 (triangles) post CD4 T cell transfer. Data is pooled from
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incubation in a MHCII-deficient environment prior to Tam treatment does not lead to
enhanced encephalitogenicity of donor CD4 T cells. Indeed, it is apparent that B cells are suffi-
cient to provide the necessary APC functions to rapidly re-stimulate rested effector memory T
cells to initiate EAE symptoms.
Discussion
The contributions of antigen specificity, antigen presentation, and cytokine production by
individual APC populations on secondary T cell activation are complex and poorly under-
stood. In MS and EAE, variation in T cell activation and effector lineage may be due to subtle
differences in the abilities of APCs to acquire and present certain antigens at different times.
For example, B6 mice are susceptible to MOG35-55 peptide-induced active EAE even if MHCII
expression is restricted to DCs or if B cells are genetically ablated [23, 28, 30, 31]. However,
resistance to MOG protein-induced active EAE can be seen in B cell deficient mice, mice with
DC-specific MHCII expression, or mice in which B cells are MHCII deficient [28, 32, 33].
Taken together, it is apparent that B cell antigen presentation is critical for supporting CNS
auto-reactivity to whole protein antigens.
Whether B cells facilitate initial CD4 T cell activation toward protein antigens in EAE has
not been directly examined to date. In restricting MHCII expression to B cells, we found that
the transgenic combination of B and T cell receptor specificities for MOG no longer evoked
spontaneous inflammatory demyelination within the spinal cord (Table 1). While it is possible
that 2D2xCD19-BMHCIIxIgHMOG mice do not develop spontaneous EAE due to the incom-
plete reconstitution of CD4 T cells by thymic grafting, our method has been utilized previously
with success [23] and wild-type levels of CD4 T cells can be observed in secondary lymphoid
tissue 9 weeks post-graft [23]. Other constraints such as a limited humoral MOG response in
2D2xCD19-BMHCIIxIgHMOG mice are unlikely to limit inflammatory demyelinating disease, as
we believe that soluble MOG-specific antibody is not essential for EAE development. This is
based on our observation that passive transfer of MOG-specific antibodies is not sufficient for
disease development in CD19-BMHCII mice [15] and the observation by the Zamvil group that
mice in which MOG-specific antibody is tethered to B cells (and therefore incapable of being
secreted) are susceptible to EAE [33]. While we did not collect serum from our cohort of
2D2xIgHMOG mice, either with or without MHCII expression restricted to B cells, we have
detected MOG-specific IgG in CD19-BMHCIIxIgHMOG mice, suggesting that antibody produc-
tion in 2D2xCD19-BMHCIIxIgHMOG mice would not be absent or deficient. The lack of sponta-
neous EAE or optic neuritis in 2D2xCD19-BMHCIIxIgHMOG mice is in agreement with the
previously reported limitations for B cells to prime CD4 T cells [22, 34]. On the other hand, B
cells can indeed prime naïve T cells as long as valid B cell antigens are delivered to them [35].
Hence, in the EAE model, limitations in B cell APC function may be rooted in restricted access
to relevant auto-antigens sequestered in the CNS. Hence, the responsibility for CD4 T cell acti-
vation and initiation of demyelination in spontaneous EAE most likely falls on DCs, which
have been found to be capable of independently initiating spontaneous optic neuritis [23].
Whether the physical location of DCs in and around the CNS [36, 37] or the intrinsic ability
CD20-BMHCIIxIgHMOG mice, UBCMHCII mice, and IAßbstopflox/floxxIgHMOG (Cre-) littermate controls from 9 different experiments with n = 3–5 mice at each time
point prior to Tam treatment. Significance determined by Kruskal-Wallis test and Dunn’s correction for multiple comparisons. (B-D) Mean ± SEM frequency of B cells
and donor CD4 T cells as a percent of total mononuclear cells in the brains (left) and spinal cords (right) harvested UBCMHCII (red squares) and CD20-BMHCIIxIgHMOG
(blue circles) mice approximately three days post EAE onset when mice were treated with Tam at (B) week 1, (C) week 2, or (D) week 3 post encephalitogenic CD4 T cell
transfer. Data is pooled from 9 different experiments with n = 1–5 mice per genotype at each time point evaluated. Significance determined by Mann-Whitney test with
two-tailed p value.
https://doi.org/10.1371/journal.pone.0199694.g005
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for DCs to prime CD4 T cells [38] bestows this capacity for disease initiation is not apparent.
Clearly, these features and others are not mutually exclusive.
Given the limitations for B cell antigen presentation in initiating disease, along with the
restrictions in eliciting full recall production of cytokines by MOG-specific CD4 T cells in sec-
ondary responses [22], we sought to assess the limitations of B cells in supporting cognate CD4
T cell-mediated CNS autoimmunity after priming during EAE. Using a Tam-inducible
MHCII expression system, we now show that antigen presentation by B cells is sufficient to
induce EAE signs just as rapidly as EAE induced by a full complement of MHCII+ APCs. This
result is contrary to our expectations given the reproducible delay in disease onset when B cells
function as the sole APC during EAE [15]. Our findings raise questions regarding what drives
accelerated disease onset in CD20-BMHCIIxIgHMOG mice. One critical component of neuro-
inflammation worthy of consideration is lymphocyte trafficking. For example, the reduced
variability in B cell frequency detected in the CNS of CD20-BMHCIIxIgHMOG mice with EAE
induced by Tam administration after T cell transfer (Fig 5B–5D) could be explained by chro-
nological changes in the concentration of chemotactic factors driving lymphocytes to the CNS.
This theory could also explain the increasingly rapid onset of EAE symptoms observed for
CD20-BMHCIIxIgHMOG mice treated with Tam after CD4 T cell transfer, as immune cells may
traffic to, or organize within, the CNS more quickly if chemokines promoting B cell accumula-
tion were up-regulated.
Our data support a model in which non-B cell APCs prime CD4 T cells toward myelin anti-
gens, enabling subsequent cognate interactions with B cell APCs to support auto-reactive B
cell proliferation and differentiation. Clinical studies have demonstrated that memory B cells
and plasmablasts are the most common B cell subtype in the CSF of patients with MS [39].
This expansion of antigen-specific B cells during CNS autoimmunity could amplify cognate
interactions between dysregulated B and CD4 T cells, which in turn could independently drive
neuro-inflammation and relapses at later stages of MS. The high frequency of antigen-specific
B cells in our EAE system may imitate the prevalence or expansion of B cells in MS patients
[40–42]. During an MS remission, previously primed encephalitogenic T cells rest in the
periphery (reflected in our EAE model as the period of time prior to Tam treatment). Of note,
peripheral B cells from relapsing-remitting MS patients exhibit exaggerated pro-inflammatory
cytokine responses that can directly promote T cell activation [43–45]. Increased MHCII
expression promotes lymphocyte trafficking to the myelin-containing CNS compartment to
initiate plaque formation (mimicked by what we observed soon after Tam treatment). It is pos-
sible that BCDTs eliminate pathogenic B cell antigen presentation, reducing germinal center
Fig 6. (A-D) Mean ± SEM of the geometric mean fluorescence intensity of activation marker expression on donor CD4 T cells harvested from spleens of
recipient mice at week 1 (circles), week 2 (squares), or week 3 (triangles) post CD4 T cell transfer. Data is pooled from CD20-BMHCIIxIgHMOG mice, UBCMHCII
mice, and IAßbstopflox/floxxIgHMOG (Cre-) littermate control recipients from five independent experiments with n = 2–4 mice per time point evaluated.
Significance tested by one way ANOVA with Tukey’s test for multiple comparisons. Geometric mean fluorescence intensity of (A) CD44, (B) CD62L, (C)
CD25, and (D) CD69 expression on donor CD4 T cells. (E) Frequency of IFNγ-expressing donor CD4 T cells pre-transfer and following in vivo incubation for
three weeks in MHCII-deficient hosts. Graph is representative of n = 5 independent experiments with at least two mice from each genotype. Donor T cells were
harvested from the spleen. Significance tested by Kruskal-Wallis test and Dunn’s correction for multiple comparisons.
https://doi.org/10.1371/journal.pone.0199694.g006
Table 2. Accelerated EAE is not induced by CD4 T cells harvested from MHCII-deficient hosts.
Recipient Genotype Donor CD4 T cells Incidence of EAE Mean Day of onset (± SEM)
WT in vivo incubated 8/9 6.2 ± 0.6
CD19-BMHCIIxIgHMOG in vivo incubated 9/13 16.7 ± 2.3
  3 weeks
https://doi.org/10.1371/journal.pone.0199694.t002
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reactions that may be occurring in the periphery and CNS. Studying the interdependency and
amplification of pro-inflammatory interactions between dysregulated lymphocytes could lead
to more targeted therapeutic interventions that specifically ablate the pathogenic effects of B
cells in situ.
The reproducibly rapid onset of EAE that we have demonstrated shows that the time
required for B cell trafficking from the periphery to the CNS is not a major contribution to the
observed delay in disease onset for CD19-BMHCIIxIgr mice. However, our findings raise ques-
tions about where antigen presentation needs to occur in the context of B cell-driven CNS
autoimmunity. While germinal center reactions mainly occur in the spleen and lymph nodes,
various reports describe formation of functional ectopic lymphoid follicles in the CNS of MS
patients and in mice with EAE [46–48]. Exclusion of B cells from the CNS results in reduced
severity of EAE induced by rhMOG yet exacerbates EAE induced by MOG35-55 peptide, indi-
cating that access to the CNS is required for EAE mediated by B cell antigen presentation yet
can also be important for regulatory B cells to ameliorate disease [49–51]. In contrast, Tesfa-
giorgis et al. found that antigen-nonspecific B cells are recruited to the CNS compartment
while myelin-specific B cells remain in the peripheral draining lymph nodes in a model of
active EAE that requires B cells [52]. In our model, the relative infrequency of B cells observed
in the CNS of mice that develop EAE may reflect the ease with which MOG-specific B cells
capture their soluble protein antigens to present to T cells within the CNS compartment. The
formation of ectopic lymphoid follicles in the CNS could create an environment in which very
few B cells have ready access to antigen and ample interactions with many cognate encephali-
togenic CD4 T cells.
Overall, the results described herein reveal that myelin-specific B cells are not able to sup-
port spontaneous EAE, although they have the potential to rapidly induce EAE with similar
kinetics as WT APCs. Our new inducible MHCII expression EAE system enables precise con-
trol of the timing of cognate interactions between B cells and CD4 T cells, revealing that B cells
do not harbor an intrinsic deficit in the promotion of auto-reactive CD4 T cell responses tar-
geting the CNS.
Supporting information
S1 Fig. Pre-tamoxifen immune cells do not accumulate within the spinal cord over time.
Flow cytometric analysis was used to determine mean +/- SEM absolute number of B cells (A)
and CD4 T cells (B) isolated from spinal cords (SC). CD20-BMHCIIxIgHMOG mice, UBCMHCII
mice, and Cre-IAßbstopflox/floxxIgHMOG littermate controls harvested at week 1 (filled circles),
week 2 (squares), or week 3 (triangles) post CD4 T cell transfer in comparison to lymphocytes
in the spinal cords of naïve WT mice (open circles). Graphs show absolute number of donor
CD4 T cells for mice harvested prior to Tam treatment and number of endogenous CD4 T
cells from WT mice. Data is pooled from CD20-BMHCIIxIgHMOG mice, UBCMHCII mice, and
Cre- Cre-IAßbstopflox/floxxIgHMOG littermate controls from 9 different experiments with
n = 3–5 mice at each time point prior to Tam treatment. Significance determined by Kruskal-
Wallis test with Dunn’s correction for multiple comparisons, with alpha = 0.05.
(TIFF)
S2 Fig. Frequency of pro-inflammatory encephalitogenic T cells before and after transfer
to MHCII-deficient hosts. Intracellular cytokine expression of IFNγ, IL-17, and GM-CSF by
CD4 T cells prior to adoptive transfer is represented by black circles. After ‘resting’ in MHCII-
deficient mice for 3 weeks, CD4 T cells were harvested from spleens of UBCMHCII (red
squares), CD20-BMHCIIxIgHMOG (blue circles) or CD20Tam-Cre-IAßbstopflox/floxxIgHMOG
(white circles) littermates and tested for intracellular cytokine expression. Kruskal-Wallis
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nonparametric test with Dunn’s correction for multiple comparisons did not identify signifi-
cant differences in the percentage of T cells expressing various cytokines after incubation in
MHCII-deficient mice with different genotypes (p>0.05).
(TIFF)
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